{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:07:53Z","timestamp":1788541673796,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Johnson & Johnson, Canada"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-14490-5","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T07:19:18Z","timestamp":1751354358000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Exploring what matters most to patients in relapsed refractory multiple myeloma treatment: a Canadian discrete choice experiment with patients, caregivers and physicians"],"prefix":"10.1186","volume":"25","author":[{"given":"Rebekah","family":"Hall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gin Nie","family":"Chua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie","family":"Macfarlane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard K","family":"Plante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Soltys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arleigh","family":"McCurdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Elias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessy","family":"Ranger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"14490_CR1","unstructured":"Canadian Cancer Statistics Advisory Committee in collaboration with the Canadian Cancer Society, Statistics Canada and the Public Health Agency of Canada. Canadian Cancer Statistics 2023. Toronto, ON: Canadian Cancer Society; 2023. Available at: https:\/\/www.cancer.ca\/Canadian-Cancer-Statistics-2023-EN."},{"key":"14490_CR2","doi-asserted-by":"publisher","first-page":"5859","DOI":"10.1007\/s00520-022-06979-7","volume":"30","author":"N Nathwani","year":"2022","unstructured":"Nathwani N, Bell J, Cherepanov D, Sowell FG, Shah R, McCarrier K, et al. Patient perspectives on symptoms, health-related quality of life, and treatment experience associated with relapsed\/refractory multiple myeloma. Support Care Cancer. 2022;30:5859\u201369.","journal-title":"Support Care Cancer"},{"key":"14490_CR3","doi-asserted-by":"publisher","first-page":"204062072110274","DOI":"10.1177\/20406207211027463","volume":"12","author":"JP MacEwan","year":"2021","unstructured":"MacEwan JP, Majer I, Chou JW, Panjabi S. The value of survival gains from therapeutic innovations for US patients with relapsed\/refractory multiple myeloma. Ther Adv Hematol. 2021;12:20406207211027464.","journal-title":"Ther Adv Hematol."},{"key":"14490_CR4","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S1470-2045(20)30756-7","volume":"22","author":"P Moreau","year":"2021","unstructured":"Moreau P, Kumar SK, San Miguel J, Davies F, Zamagni E, Bahlis N, et al. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol. 2021;22:e105\u201318.","journal-title":"Lancet Oncol."},{"key":"14490_CR5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41571-020-0427-6","volume":"18","author":"L Mikkilineni","year":"2021","unstructured":"Mikkilineni L, Kochenderfer JN. CAR T cell therapies for patients with multiple myeloma. Nat Rev Clin Oncol. 2021;18:71\u201384.","journal-title":"Nat Rev Clin Oncol."},{"key":"14490_CR6","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.2147\/PPA.S259612","volume":"14","author":"S Fifer","year":"2020","unstructured":"Fifer S, Galinsky J, Richard S. Myeloma patient value mapping: a discrete choice experiment on myeloma treatment preferences in the UK. Patient Prefer Adher. 2020;14:1283\u201393.","journal-title":"Patient Prefer Adher."},{"key":"14490_CR7","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1186\/s12885-020-07018-6","volume":"20","author":"SJ Fifer","year":"2020","unstructured":"Fifer SJ, Ho K-A, Lybrand S, Axford LJ, Roach S. Alignment of preferences in the treatment of multiple myeloma\u2013 a discrete choice experiment of patient, carer, physician, and nurse preferences. BMC Cancer. 2020;20:546.","journal-title":"BMC Cancer."},{"key":"14490_CR8","first-page":"Doc10","volume":"5","author":"AC M\u00fchlbacher","year":"2008","unstructured":"M\u00fchlbacher AC, Lincke H-J, N\u00fcbling M. Evaluating patients\u2019 preferences for multiple myeloma therapy, a discrete-choice-experiment. Psychosoc Med. 2008;5:Doc10.","journal-title":"Psychosoc Med."},{"key":"14490_CR9","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.2147\/PPA.S183187","volume":"12","author":"T Wilke","year":"2018","unstructured":"Wilke T, Mueller S, Bauer S, Pitura S, Probst L, Ratsch BA, et al. Treatment of relapsed refractory multiple myeloma: which new PI-based combination treatments do patients prefer? Patient Prefer Adherence. 2018;12:2387\u201396.","journal-title":"Patient Prefer Adherence"},{"key":"14490_CR10","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.jval.2023.01.016","volume":"26","author":"T Tervonen","year":"2023","unstructured":"Tervonen T, Duenas A, Collacott H, Lam A, Gries KS, Carson R, et al. Current health state affected patient preferences more than disease status: a discrete choice experiment in multiple myeloma. Value in Health. 2023;26:909\u201317.","journal-title":"Value in Health."},{"key":"14490_CR11","doi-asserted-by":"publisher","first-page":"1027353","DOI":"10.3389\/fonc.2022.1027353","volume":"12","author":"R Janssens","year":"2022","unstructured":"Janssens R, Lang T, Vallejo A, Galinsky J, Morgan K, Plate A, et al. What matters most to patients with multiple myeloma? A Pan-European patient preference study. Front Oncol. 2022;12:1027353.","journal-title":"Front Oncol."},{"key":"14490_CR12","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1634\/theoncologist.2017-0257","volume":"23","author":"D Postmus","year":"2018","unstructured":"Postmus D, Richard S, Bere N, van Valkenhoef G, Galinsky J, Low E, et al. Individual trade-offs between possible benefits and risks of cancer treatments: results from a stated preference study with patients with multiple myeloma. Oncologist. 2018;23:44\u201351.","journal-title":"Oncologist"},{"key":"14490_CR13","unstructured":"Myeloma UK. Measuring Patient Preferences An exploratory study to determine how patient preferences data could be used in health technology assessment (HTA) [Internet]. 2019 [cited 2025 Jun 19]. Available from: https:\/\/www.myeloma.org.uk\/wp-content\/uploads\/2024\/09\/NICE-Patient-Preferences-Report.pdf."},{"key":"14490_CR14","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s10198-010-0218-6","volume":"12","author":"AC M\u00fchlbacher","year":"2011","unstructured":"M\u00fchlbacher AC, N\u00fcbling M. Analysis of physicians\u2019 perspectives versus patients\u2019 preferences: direct assessment and discrete choice experiments in the therapy of multiple myeloma. Euro J Health Econ. 2011;12:193\u2013203.","journal-title":"Euro J Health Econ"},{"key":"14490_CR15","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.2217\/fon-2022-0378","volume":"18","author":"L Batchelder","year":"2022","unstructured":"Batchelder L, Philpott S, Divino V, Boytsov N, Maiese EM, Hogea C, et al. Physician treatment preferences for relapsed\/refractory multiple myeloma: a discrete choice experiment. Future Oncol. 2022;18:2843\u201356.","journal-title":"Future Oncol."},{"key":"14490_CR16","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.clinthera.2017.12.012","volume":"40","author":"T Bolt","year":"2018","unstructured":"Bolt T, Mahlich J, Nakamura Y, Nakayama M. Hematologists\u2019 preferences for first-line therapy characteristics for multiple myeloma in Japan: attribute rating and discrete choice experiment. Clin Ther. 2018;40:296\u2013308.e2.","journal-title":"Clin Ther."},{"key":"14490_CR17","doi-asserted-by":"publisher","first-page":"573","DOI":"10.2147\/PPA.S345906","volume":"16","author":"D Auclair","year":"2022","unstructured":"Auclair D, Mansfield C, Fiala MA, Chari A, Cole CE, Kaufman JL, et al. Preferences and priorities for relapsed multiple myeloma treatments among patients and caregivers in the United States. Patient Prefer Adherence. 2022;16:573\u201385.","journal-title":"Patient Prefer Adherence."},{"key":"14490_CR18","doi-asserted-by":"publisher","first-page":"1271657","DOI":"10.3389\/fmed.2023.1271657","volume":"10","author":"C Thomas","year":"2023","unstructured":"Thomas C, Ailawadhi S, Popat R, Kleinman D, Ross MM, Gorsh B, et al. Treatment preferences of patients with relapsed or refractory multiple myeloma in the United States, United Kingdom, Italy, Germany, France, and Spain: results from a discrete choice experiment. Front Med (Lausanne). 2023;10:1271657.","journal-title":"Front Med (Lausanne)."},{"key":"14490_CR19","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s40271-020-00449-0","volume":"14","author":"E van Overbeeke","year":"2021","unstructured":"van Overbeeke E, Forrester V, Simoens S, Huys I. Use of Patient preferences in health technology assessment: perspectives of Canadian, Belgian and German HTA representatives. Patient - Patient-Centered Outcomes Res. 2021;14:119\u201328.","journal-title":"Patient - Patient-Centered Outcomes Res"},{"key":"14490_CR20","unstructured":"U.S. Food & Drug Administration. List of Patient Preference-Sensitive Priority Areas| FDA. 2020. https:\/\/www.fda.gov\/about-fda\/cdrh-patient-science-and-engagement-program\/list-patient-preference-sensitive-priority-areas. Accessed 22 Jan 2024."},{"key":"14490_CR21","unstructured":"Canada\u2019s Drug Agency. Procedures for Reimbursement Reviews [Internet]. 2020. Available from: https:\/\/www.cda-amc.ca\/reimbursement-review-reports."},{"key":"14490_CR22","unstructured":"Canada\u2019s Drug Agency. Health Technology Review Drugs Health Technologies Health Systems Methods Guide for Health Technology Assessment [Internet]. 2025. Available from: https:\/\/www.cda-amc.ca\/sites\/default\/files\/MG%20Methods\/MG0030-Quantitative-Methods-Manual-Line-Numbered.pdf."},{"key":"14490_CR23","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2165\/00019053-200826080-00004","volume":"26","author":"E Lancsar","year":"2008","unstructured":"Lancsar E, Louviere J. Conducting discrete choice experiments to inform healthcare decision making. Pharmacoeconomics. 2008;26:661\u201377.","journal-title":"Pharmacoeconomics."},{"key":"14490_CR24","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jval.2010.11.013","volume":"14","author":"JFP Bridges","year":"2011","unstructured":"Bridges JFP, Hauber AB, Marshall D, Lloyd A, Prosser LA, Regier DA, et al. Conjoint analysis applications in health - a checklist: a report of the ISPOR good research practices for conjoint analysis task force. Value in Health. 2011;14:403\u201313.","journal-title":"Value in Health."},{"key":"14490_CR25","unstructured":"Macfarlane B, Plante K, Shi K, Soltys s, Wywial E, Elias M, et al. A study of patient, caregiver and health care professional preferences in the treatment of relapsed or refractory multiple myeloma. In: CADTH Symposium. 2023."},{"key":"14490_CR26","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1186\/s12885-021-08527-8","volume":"21","author":"C Pritlove","year":"2021","unstructured":"Pritlove C, Jassi M, Burns B, McCurdy A. The work of managing multiple myeloma and its implications for treatment-related decision making: a qualitative study of patient and caregiver experiences. BMC Cancer. 2021;21:793.","journal-title":"BMC Cancer."},{"issue":"Supplement 1","key":"14490_CR27","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1182\/blood-2018-99-113087","volume":"132","author":"D Auclair","year":"2018","unstructured":"Auclair D, Mansfield C, Chari A, Cole CE, Fiala MA, Kaufman JL, et al. Patient treatment preferences for relapsed\/refractory multiple myeloma: are patients willing to trade off efficacy for tolerability? Blood. 2018;132(Supplement 1):614\u2013614.","journal-title":"Blood."},{"key":"14490_CR28","doi-asserted-by":"publisher","first-page":"S428","DOI":"10.1016\/S2152-2650(21)01955-8","volume":"21","author":"C Thomas","year":"2021","unstructured":"Thomas C, Gelhorn H, Mulnick S, Popat R, Ailawadhi S, Kleinman D, et al. MM-200: a qualitative study of patients\u2019 preferences for the treatment of Relapsed or Refractory Multiple Myeloma (RRMM) in the United States, United Kingdom, France, and Germany. Clin Lymphoma Myeloma Leuk. 2021;21:S428.","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"14490_CR29","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1001\/jamaoncol.2019.3338","volume":"5","author":"MJ Raphael","year":"2019","unstructured":"Raphael MJ, Robinson A, Booth CM, O\u2019Donnell J, Palmer M, Eisenhauer E, et al. The value of progression-free survival as a treatment end point among patients with advanced cancer. JAMA Oncol. 2019;5:1779.","journal-title":"JAMA Oncol."},{"key":"14490_CR30","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ygyno.2015.11.030","volume":"140","author":"LE Minion","year":"2016","unstructured":"Minion LE, Coleman RL, Alvarez RD, Herzog TJ. Endpoints in clinical trials: what do patients consider important? A survey of the ovarian cancer national alliance. Gynecol Oncol. 2016;140:193\u20138.","journal-title":"Gynecol Oncol."},{"key":"14490_CR31","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol. 2023;20:359\u201371.","journal-title":"Nat Rev Clin Oncol"},{"key":"14490_CR32","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.2217\/fon-2022-0421","volume":"18","author":"K Birch","year":"2022","unstructured":"Birch K, Snider JT, Chiu K, Baumgardner J, Wade SW, Shah G. Patient preferences for treatment in relapsed\/refractory diffuse large B-cell lymphoma: a discrete choice experiment. Future Oncol. 2022;18:2791\u2013804.","journal-title":"Future Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14490-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14490-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14490-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T07:19:22Z","timestamp":1751354362000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14490-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14490"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14490-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"13 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in line with the principles of the Declaration of Helsinki. This study was reviewed and approved by Pearl IRB (IRB ID: 22-ISPO-171), an AAHRPP-accredited independent institutional review board. All participants provided informed consent prior to participating in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RH and GNC are employees of Acaster Lloyd Consulting, Ltd., which was paid by Janssen Inc. for work related to this study. BM, KS, SS are employees of Janssen Inc., a Johnson & Johnson company and own Johnson & Johnson stock and stock options.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1095"}}